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Key Points
• Uncomplicated malaria is where the person has symptomatic infection with malaria parasites but no signs of vital
organ disturbance.
Uncomplicated malaria can progress to severe malaria, become chronic, or resolve, depending on host immunity
and prompt access to appropriate treatment.
Severe malaria is more likely to develop in people with no prior immunity, and accounts for over one million deaths
worldwide each year.
The choice between treatment regimens depends partly on background drug resistance patterns in the relevant
country or region.
• Evidence suggests that artemether–lumefantrine  is more effective than amodiaquine plus sulfadox-
ine–pyrimethamine.
• Artesunate plus amodiaquine  is more effective at curing a current infection than amodiaquine plus sulfadox-
ine–pyrimethamine, but, in terms of people being parasite free at day 28, there is little to choose between them,
since the risk of new infections appears greater with artesunate plus amodiaquine.
• Amodiaquine plus sulfadoxine–pyrimethamine achieved higher cure rates than artesunate plus sulfadox-
ine–pyrimethamine . Gametocyte clearance was better with artesunate plus sulfadoxine–pyrimethamine.
Public health specialists believe that amodiaquine resistance will progress rapidly and limit the usefulness of the
non-artemisinin combination if it is used regularly. On the other hand, amodiaquine and sulfadoxine–pyrimethamine
are currently available in many countries, whereas artemisinin supplies are limited.
• Evidence suggests that a six-dose regimen of artemether–lumefantrine  is more effective than a four-dose regimen.
• Both artemether–lumefantrine (6 doses)  and artesunate plus amodiaquine were effective, but artemether–lume-
fantrine (6 doses) was superior in some trials.
• Artesunate plus mefloquine  performs better than artemether–lumefantrine in terms of cure in areas where this has
been studied.
Infectious diseases
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• The choice between artesunate plus amodiaquine  and artesunate plus sulfadoxine–pyrimethamine depends on
background drug resistance patterns in the relevant country or region.
DEFINITION Malaria is a parasite transmitted by Anopheles mosquitoes.There are four types of human malaria:
falciparum, vivax, ovale, and malariae. The falciparum type is the most important cause of illness
and death, and Plasmodium falciparum, the responsible organism, is known to develop resistance
to antimalarial drugs. [1] This review covers treatments for falciparum malaria only, in a population
of adults and children living in endemic malarial areas, exposed (seasonally or all year round) to
malaria. It does not cover treatment of malaria in non-immune travellers, pregnant women, and
people infected with HIV. Repeated episodes of falciparum malaria result in temporary and incom-
plete immunity. Therefore, adults living in areas where malaria is common are often found to be
“semi-immune” — presenting with asymptomatic or chronic forms of malaria, with clinical episodes
attenuated by their immunity. “ Severe malaria ” is defined as a form of symptomatic malaria with
signs of vital organ disturbance (World Health Organization 2000). [1]  Any person with symptomatic
malaria who does not develop any such signs is defined as having “ uncomplicated malaria ”.




Malaria is a major health problem in the tropics, with 300–500 million new clinical cases annually,
most of them cases of uncomplicated malaria. An estimated 1.1–2.7 million deaths occur annually
as a result of severe falciparum malaria. [1]
AETIOLOGY/
RISK FACTORS
The malaria parasite is transmitted by infected Anopheles mosquitoes. Risk factors for developing
the disease include exposure to infected mosquitoes (living in an endemic area; housing that allows
mosquitoes to enter, and absence of mosquito nets; and living in an area where Anopheles
mosquitoes can thrive). Risk factors in relation to severity of the illness relate to host immunity,
determined mainly by exposure to the parasite, and therefore varying with level of transmission in
the area, and the age of the host. Malaria is uncommon in the first 6 months of life (fetal haemoglobin
is protective); it is, however, common in children over 6 months of age. In areas of intense trans-
mission, infection is attenuated by host immunity in older age groups; however, morbidity and
mortality can also be high in adults in areas of less-intense transmission.
PROGNOSIS Uncomplicated malaria may progress to severe malaria, become chronic, or resolve with effective
treatment or the development of improved immunity. The outcome is therefore dependent on host
immunity and prompt access to effective treatment. In the absence of effective treatment, people
with no or low immunity are at increased risk of developing severe malaria (see review on malaria:
severe, life threatening) resulting in high morbidity and mortality.
AIMS OF
INTERVENTION
To alleviate symptoms; to prevent progression to severe disease; to cure the infection, with minimal
adverse effects.
OUTCOMES Clinical failure  rate (defined as the proportion of people with symptoms of malaria plus parasitaemia
at or before day 28); clinical failure rate at time frames other than day 28 (where no 28-day evidence
is available); total failure  rate (defined as clinical failure rate plus the proportion of people with
asymptomatic parasitaemia at day 28); parasitological failure  rate (defined as proportion of people
with parasitaemia at day 28); parasitological failure rate at time frames other than day 28 (where
no 28-day evidence is available); early treatment failure (evidence of clinical or parasitological
symptoms during the first 3 days of follow-up); adequate clinical and parasitological response
(ACPR) ; parasitological conversion  rate; parasitological success  rate; fever-clearance time;
gametocytaemia  rate; gametocyte clearance time ; rate of progression to severe disease; need
for rescue treatment (quinine treatment given in the case of treatment failure); and adverse effects
requiring admission to hospital or discontinuation of treatment. Day 14 failure does not sufficiently
predict treatment failure  in trials of drugs with a terminal elimination half life of more than a few
days. [2]  Some of the differences in rates of treatment failure at day 14 may result from differences
in elimination kinetics between the drugs. For comparisons of most drugs, follow-up to day 28 is
adequate, although shorter follow-up data are reported if 28-day outcomes are not available. With
mefloquine, however, 42-day follow up is preferable because of its longer half life. Where 42-day
or longer follow-up data are not available, 28-day outcomes are reported.
METHODS BMJ Clinical Evidence search and appraisal November 2006. The following databases were used
to identify studies for this systematic review: Medline 1966 to November 2006, Embase 1980 to
November 2006, and The Cochrane Database of Systematic Reviews and Cochrane Central
Register of Controlled Clinical Trials 2006, Issue 4. Additional searches were carried out using
these websites: NHS Centre for Reviews and Dissemination (CRD) — for Database of Abstracts
of Reviews of Effects (DARE) and Health Technology Assessment (HTA), Turning Research into
© BMJ Publishing Group Ltd 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Malaria: uncomplicated, caused by Plasmodium falciparum
Infectious diseases
Practice (TRIP), and National Institute for Health and Clinical Excellence (NICE). Abstracts of the
studies retrieved from the initial search were assessed by an information specialist. Selected
studies were then sent to the author for additional assessment, using predetermined criteria to
identify relevant studies. Study design criteria for evaluation in this review were: published system-
atic reviews and RCTs in any language, including open studies, and containing more than 20 indi-
viduals of whom more than 80% were followed up. There was no minimum length of follow-up re-
quired to include studies. In addition, we use a regular surveillance protocol to capture harms alerts
from organisations such as the US Food and Drug Administration (FDA) and the UK Medicines
and Healthcare products Regulatory Agency (MHRA), which are added to the reviews as required.
We conducted the search and identified the questions in collaboration with the World Health Orga-
nization Malaria Technical Guidelines Development Group for evidence-based guidelines for un-
complicated malaria treatment that draw explicitly on this review.We have excluded certain questions
irrelevant to current policies because of drug resistance — namely those examining the following:
monotherapy (globally) with chloroquine, sulfadoxine–pyrimethamine, amodiaquine; combination
therapy with chloroquine (globally); and non-artemisinin combinations (and artemisinin in combination
with amodiaquine or sulfadoxine–pyrimethamine) in South East Asia. In addition, because quinine
has traditionally been reserved for treatment failures or severe malaria because of its toxicity, it is
not reviewed here. We have performed a GRADE evaluation of the quality of evidence for interven-
tions included in this review ( see table, p 13 ).
QUESTION Are artemisinin combination treatments more effective than non-artemisinin combinations
treatments in people living in endemic areas (excluding South East Asia)?
OPTION ARTEMETHER–LUMEFANTRINE (6 DOSES) VERSUS AMODIAQUINE PLUS SULFADOX-
INE–PYRIMETHAMINE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Treatment failure
Artemether–lumefantrine compared with amodiaquine plus sulfadoxine–pyrimethamine Artemether–lumefantrine is
more effective at reducing treatment failure rates at 28 days compared with amodiaquine plus sulfadoxine ( high-
quality evidence ).
For GRADE evaluation of malaria: uncomplicated, caused by Plasmodium falciparum, see table, p 13 .
Benefits: We found one systematic review (search date 2005) [3] which identified one RCT. [4] The primary
outcome measure of the review was total failure . The review reported significantly fewer total
failures on day 28 with artemether–lumefantrine (6 doses) compared with amodiaquine plus sulfa-
doxine–pyrimethamine (1 RCT, 948 children in Tanzania, total failure at day 28: 141/485 [29%]
with artemether–lumefantrine v 369/463 [80%] with amodiaquine plus sulfadoxine–pyrimethamine;
RR 0.36, 95% CI 0.32 to 0.42). [3]  It reported that artemether–lumefantrine (6 doses) also signifi-
cantly reduced gametocyte carriage at day 14 (617 children, gametocyte carriage on day 14: 20/333
[6%] with artemether–lumefantrine v 73/284 [26%] with amodiaquine plus sulfadox-
ine–pyrimethamine; RR 0.23, 95% CI 0.15 to 0.37).
Harms: The RCT included in the review reported one death in the amodiaquine plus sulfadox-
ine–pyrimethamine group shortly after randomisation (considered to be caused by disease severity
at the point of entry into the study), and one death at day 20 in the artemether–lumefantrine group.
[4]
Comment: Concealment was adequate in the trial. [3] The trial was conducted in an area where malaria
transmission is perennial, and where a high level of resistance to sulfadoxine–pyrimethamine and
chloroquine has been recorded. [4]
Clinical guide:
Artemether–lumefantrine is more effective than amodiaquine plus sulfadoxine–pyrimethamine.
OPTION ARTESUNATE (3 DAYS) PLUS AMODIAQUINE VERSUS AMODIAQUINE PLUS SULFADOX-
INE–PYRIMETHAMINE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Treatment failure
Artesunate plus amodiaquine compared with amodiaquine plus sulfadoxine– pyrimethamine Artesunate plus
amodiaquine may be more effective than amodiaquine plus sulfadoxine–pyrimethamine in reducing treatment failure
rates (excluding new infections) at 28 days in children with uncomplicated malaria, but may be no more effective in
the need for rescue therapy ( low-quality evidence ).
Fever resolution
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Artesunate plus amodiaquine compared with amodiaquine plus sulfadoxine–pyrimethamine Artesunate plus amodi-
aquine is more effective at 3 days in reducing the time to fever resolution compared with amodiaquine plus sulfadoxine-
pyrimethamine ( moderate-quality evidence ).
Recrudescence
Artesunate plus amodiaquine compared with amodiaquine plus sulfadoxine–pyrimethamine Artesunate plus amodi-
aquine may increase recrudescence rates at 28 days compared with amodiaquine plus sulfadoxine–pyrimethamine
(low-quality evidence).
For GRADE evaluation of malaria: uncomplicated, caused by Plasmodium falciparum, see table, p 13 .
Benefits: We found three RCTs. [4] [5] [6] The first three-arm RCT compared artesunate plus amodiaquine
versus amodiaquine plus sulfadoxine–pyrimethamine. [5]  It found that artesunate plus amodiaquine
significantly reduced the risk of clinical treatment failure  compared with amodiaquine plus sulfa-
doxine–pyrimethamine at 28 days, although there was no significant difference in need for rescue
therapy (278 children in Uganda aged 6 months to 10 years, randomised to the artesunate plus
amodiaquine and amodiaquine plus sulfadoxine–pyrimethamine arms; polymerase chain reaction-
adjusted clinical treatment failure  [per protocol analysis]: 9% with amodiaquine plus sulfadox-
ine–pyrimethamine v 2% with artesunate plus amodiaquine; difference 7%, 95% CI 1% to 13%;
P = 0.018; rescue treatment [per protocol analysis]: 13% with amodiaquine plus sulfadox-
ine–pyrimethamine v 12% with artesunate plus amodiaquine; difference +1%, 95% CI –7% to +9%;
P = 0.854). [5] The RCT also found that artesunate plus amodiaquine significantly reduced time to
fever resolution compared with amodiaquine plus sulfadoxine–pyrimethamine, although by day 3
fever had cleared in most children (afebrile at day 2: 101/129 [78%] with artesunate plus amodiaquine
v 83/130 [64%] with amodiaquine plus sulfadoxine–pyrimethamine; P = 0.02; afebrile at day 3:
absolute figures not presented, significance assessment not performed). The second four-arm
RCT compared artesunate plus amodiaquine versus amodiaquine plus sulfadoxine–pyrimethamine.
[4]
 It found that artesunate plus amodiaquine significantly reduced parasitological failure  and
clinical failure  rate at 28 days, and was associated with fewer gametocytes at day 14 compared
with amodiaquine plus sulfadoxine–pyrimethamine (1022 children aged 4–59 months in North East
Tanzania, randomised to artesunate plus amodiaquine and amodiaquine plus sulfadox-
ine–pyrimethamine arms; polymerase chain reaction [PCR]-adjusted parasitological failure rate:
193/472 [40%] with artesunate plus amodiaquine v 282/463 [61%] with amodiaquine plus sulfadox-
ine–pyrimethamine; OR 0.43, 95% CI 0.34 to 0.59; P < 0.0001; clinical failure rate: 52/472 [11%]
with artesunate plus amodiaquine v 87/463 [19%] with amodiaquine plus sulfadoxine–pyrimethamine;
OR 0.56, 95% CI 0.37 to 0.77; P = 0.0008; gametocytes: 38/318 [12%] with artesunate plus
amodiaquine v 73/284 [26%] with amodiaquine plus sulfadoxine–pyrimethamine; significance as-
sessment not performed). [4] The third RCT, undertaken in four separate districts in Uganda (Jinja,
Arua, Apac, Tororo), compared artesunate plus amodiaquine versus amodiaquine plus sulfadox-
ine–pyrimethamine. [6] The results were reported separately for the four sites. The RCT found that,
at two sites with high transmission, artesunate plus amodiaquine was associated with a higher risk
for recurrent infection (recrudescence [relapse caused by recurrence of the original infection] and
new infection) and new infection at day 28, with no significant difference detected at the other two
sites (1537 children in total aged 6 months or greater; PCR-unadjusted risk of recurrent infection
[per protocol analysis]: Tororo site: 59% with amodiaquine plus sulfadoxine–pyrimethamine v 74%
with artesunate plus amodiaquine, P < 0.05; Apac site: 36% v 52%, P less than 0.05; Jinja site,
28% v 19%, difference reported as not significant, P value not provided; Arua site: 53% v 51%,
difference reported as not significant, P value not provided). [6]  In contrast, the RCT found that
artesunate plus amodiaquine was associated with a lower risk of recrudescence at three sites, al-
though this only reached statistical significance at one site (Jinja site: risk difference 9%, 95% CI
3% to 15%, P = 0.009). The proportion of people with a temperature above 37.5° celcius on day
2 did not differ between the two groups at any of the sites.The proportion of people with gametocytes
during follow-up was significantly lower in the artesunate plus amodiaquine group at one of the
sites (Arua site: 49% with amodiaquine plus sulfadoxine–pyrimethamine v 36% with artesunate
plus amodiaquine; P less than 0.05), but was not significantly different between groups at the other
three sites. [6]
Harms: The first RCT found no significant difference between treatments in adverse events of moderate
or greater severity when people who needed rescue therapy were excluded from analyses (absolute
figures not reported; difference reported as not significant; P value not reported). [5]  Six serious
adverse events were reported with amodiaquine plus sulfadoxine–pyrimethamine (3 convulsions;
1 vomiting; 1 pyomyositis; and 1 thrombocytopenia, neutropenia, and anaemia) and one with
artesunate plus amodiaquine (measles). Most of these were attributable to severe malaria or other
illnesses. The child with thrombocytopenia was noted to have had it at enrolment, but it worsened
and became life threatening, and severe anaemia and neutropenia developed. A bone marrow
biopsy revealed hypoplastic marrow of undetermined cause with all cell lines present. Additional
severe laboratory-related adverse events included one case of anaemia with artesunate plus
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amodiaquine, one case of transient asymptomatic neutropenia with amodiaquine plus sulfadox-
ine–pyrimethamine, and one case of increased alanine transaminase associated with clinical
hepatitis that resolved by day 28 with amodiaquine plus sulfadoxine–pyrimethamine. In the second
RCT, one child in the amodiaquine plus sulfadoxine–pyrimethamine group died on the day of ran-
domisation; no children died in the artesunate plus amodiaquine group. [4] Severity of disease was
thought to be the probable cause of death. One other possible serious adverse event was recorded:
a child needed hospitalisation for a rash on day 20. The authors did not state in which treatment
arm this child was, but stated that the rash was thought to be unrelated to the study drug.The third
RCT found eight people with serious adverse events in the amodiaquine plus sulfadox-
ine–pyrimethamine group (2 episodes of anaemia, 2 of convulsions, 1 of oedema, 2 of mental
status change, 2 of respiratory illness, and 1 of weakness) compared with four in the artesunate
plus amodiaquine group (1 episode of anaemia, 1 of convulsions, 1 of dehydration and 1 of respi-
ratory illness). [6]  Only ten of the serious adverse events were thought to be possibly related to
study medications in the trial, but these were not disaggregated between treatment groups. Two
people died in the amodiaquine plus sulfadoxine–pyrimethamine group (1 of suspected malnutrition
and 1 of heart failure secondary to a presumed congenital heart defect).
Comment: Concealment was adequate in the three trials. [4] [5] [6] The first RCT was conducted in an urban
centre where malaria is mesoendemic, arising perennially with peaks during the two rainy seasons.
[5]
 Fourteen-day clinical treatment failure rates of 7% with amodiaquine and 2% with amodiaquine
plus sulfadoxine–pyrimethamine had been reported from the site shortly before the study began.
The authors of the second study did not comment on the malaria endemicity or resistance patterns
in the study site. [4] The third RCT was conducted in four sites; one peri-urban with medium-high
endemnicity (Jinja), and three rural with very high endemnicity (Arua, Apac and Tororo). [6]
Clinical guide:
In terms of cure of the current infection, artesunate plus amodiaquine is more effective than
amodiaquine plus sulfadoxine–pyrimethamine. In terms of people being parasite free at day 28,
there is little to choose between them, since the risk of new infections appears greater with arte-
sunate plus amodiaquine. These findings are relevant in endemic malarious areas of Africa.
OPTION ARTESUNATE (3 DAYS) PLUS SULFADOXINE–PYRIMETHAMINE VERSUS AMODIAQUINE
PLUS SULFADOXINE–PYRIMETHAMINE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Treatment failure
Artesunate plus sulfadoxine–pyrimethamine compared with amodiaquine plus sulfadoxine–pyrimethamine Artesunate
plus sulfadoxine-pyrimethamine may be less effective at reducing treatment failure rates at 28 days compared with
amodiaquine plus sulfadoxine–pyrimethamine ( very low-quality evidence ).
For GRADE evaluation of interventions for malaria: uncomplicated, caused by Plasmodium falciparum, see
table, p 13 .
Benefits: We found one systematic review [7] and two subsequent RCTs. [8] [9] The systematic review (search
date 2005, 4 RCTs, 775 people) compared artesunate plus sulfadoxine–pyrimethamine versus
amodiaquine plus sulfadoxine–pyrimethamine. [7] The review found that significantly fewer partici-
pants failed treatment with amodiaquine plus sulfadoxine–pyrimethamine compared with artesunate
plus sulfadoxine–pyrimethamine at day 28 (3 RCTs, 652 people in Uganda, Ghana, and Rwanda;
polymerase chain reaction [PCR]-unadjusted treatment failure: 43/327 [13%] with amodiaquine
plus sulfadoxine–pyrimethamine v 74/325 [23%] with artesunate plus sulfadoxine–pyrimethamine;
RR 0.59, 95% CI 0.42 to 0.83). It found that amodiaquine plus sulfadoxine–pyrimethamine also
resulted in significantly fewer treatment failures when new infections were excluded (3 RCTs, 649
people in Uganda, Ghana and Rwanda, PCR-adjusted treatment failure: 28/324 [9%] with amodi-
aquine plus sulfadoxine–pyrimethamine v 47/325 [14%] with artesunate plus sulfadox-
ine–pyrimethamine; RR 0.62, 95% CI 0.40 to 0.96). It found that gametocyte carriage was signifi-
cantly higher at day 7 with amodiaquine plus sulfadoxine–pyrimethamine compared with artesunate
plus sulfadoxine–pyrimethamine (1 RCT, 220 people in Uganda, gametocyte carriage at day 7:
40/118 [34%] with amodiaquine plus sulfadoxine–pyrimethamine v 15/102 [15%] with artesunate
plus sulfadoxine–pyrimethamine; RR 2.31, 95% CI 1.36 to 3.92). [7] The first subsequent eight-arm
RCT compared artesunate plus sulfadoxine–pyrimethamine versus amodiaquine plus sulfadox-
ine–pyrimethamine in two arms of the trial. [8]  It found similar results in the proportion of total failures
at day 28 between the two trial arms, but did not test significance between groups (147 adults and
children in Colombia; total failure at day 28: 2/57 [3.4%] with artesunate plus sulfadox-
ine–pyrimethamine v 2/90 [2.2%] with amodiaquine plus sulfadoxine–pyrimethamine; no statistical
significance test reported).The second subsequent four-arm RCT compared artesunate plus sulfa-
doxine–pyrimethamine versus amodiaquine plus sulfadoxine–pyrimethamine in Kenya. [9]  It found
that the proportion of adequate clinical parasitological response was higher with amodiaquine plus
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sulfadoxine–pyrimethamine compared with artesunate plus sulfadoxine–pyrimethamine (adequate
clinical parasitological response at day 28: 131/160 [82%] with artesunate plus sulfadox-
ine–pyrimethamine v 100/115 [87%] with amodiaquine plus sulfadoxine–pyrimethamine; no statis-
tical significance test between groups reported). It found that gametocyte prevalence over 28 days
was significantly higher with amodiaquine plus sulfadoxine–pyrimethamine, whether measured
using microscopy (P less than 0.001) or by genetic typing (P = 0.007). [9]
Harms: The systematic review reported that one participant progressed to severe malaria in the amodiaquine
plus sulfadoxine–pyrimethamine group (1 RCT, 113 people in Uganda: 1/59 with amodiaquine plus
sulfadoxine–pyrimethamine v 0/54 with artesunate plus sulfadoxine–pyrimethamine; RR 2.75, 95%
CI 0.11 to 66.1). [7] The review reported that the RCTs generally did not describe the methods
used to report adverse events, and did not provide numbers. One included RCT reported “no severe
adverse reactions attributable to treatment”; one reported “no major drug-related adverse effects”;
one reported “no severe adverse reactions to trial drugs"; and that “mild adverse reactions did not
differ between the three treatment groups”. The first subsequent RCT specifically sought adverse
effects; the paper describing these effects is in preparation. [8] The second subsequent RCT did
not report on adverse effects. [9]
Comment: Concealment was adequate in one, and unclear in three of the four RCTs included in the system-
atic review. [7]  All the included RCTs were in Africa. The RCT in Ghana was in a hyperendemic
area.There was seasonal transmission in the trials in Mozambique.There was stable transmission
with seasonal peaks in Rwanda. The trial in Uganda was in a mesoendemic area. There was sul-
fadoxine-pyrimethamine resistance described in the trials in Rwanda and Uganda. In the first sub-
sequent RCT, allocation concealment was adequate. [8]  It was conducted in an area where "the
whole population is exposed to the risk of malaria", and there is chloroquine resistance. In the
second subsequent RCT, allocation concealment was unclear. [9] The RCT was conducted in
Kenya in an area of high and perennial malaria transmission, and there is no comment on local
resistance patterns. Chloroquine and sulfadoxine-pyrimethamine resistance is common in many
areas of sub-Saharan Africa.
Clinical guide: Amodiaquine plus sulfadoxine–pyrimethamine achieved higher cure rates than
artesunate plus sulfadoxine–pyrimethamine. Gametocyte clearance was better with artesunate
plus sulfadoxine–pyrimethamine. Public health specialists believe that amodiaquine resistance will
progress rapidly and limit the usefulness of the non-artemisinin combination if it is used regularly.
On the other hand, amodiaquine and sulfadoxine–pyrimethamine are currently available in many
countries, whereas artemisinin supplies are limited.
QUESTION Which artemisinin combination treatment is most effective in people living in endemic areas?
OPTION ARTEMETHER–LUMEFANTRINE (6 DOSES) VERSUS ARTEMETHER–LUMEFANTRINE (4
DOSES) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cure rates
Six-dose regimen compared with four-dose regimen A six-dose regimen of artemether–lumefantrine is more effective
at increasing cure rates at 28 days compared with a four-dose regimen ( moderate-quality evidence ).
For GRADE evaluation of interventions for malaria: uncomplicated, caused by Plasmodium falciparum, see
table, p 13 .
Benefits: We found one systematic review (search date 2005, 1 RCT, 359 people, Thailand). [10] The RCT
identified by the review compared three artemether–lumefantrine regimens: a four-dose regimen
over 3 days, a six-dose regimen over 3 days, and a six-dose regimen over 5 days. [11] The RCT
found a significantly higher rate of parasitological cure at 28 days with the six-dose regimen given
over 3 days compared with the four-dose regimen given over 3 days (238 adults and children ran-
domised to the 3 day regimens, Thailand; polymerase chain reaction [PCR]-unadjusted parasito-
logical cure rate for intention to treat population at day 28: 96/118 [81%] with 6-dose regimen v
85/120 [71%] with 4-dose regimen; P less than 0.001; PCR-adjusted parasitological cure rate for
evaluable population: 93/96 [97%] with 6-dose regimen v 85/102 [83%] with 4-dose regimen; P
less than 0.001). [11] There was no statistically significant difference in the median fever clearance
times between the four-dose regimen and the two six-dose regimens (P value not provided). [10]
There was no statistically significant difference in the gametocyte clearance time in comparisons
between the four-dose and six-dose regimens (P = 0.5; trial authors’ calculation). [10]
Harms: The RCT identified by the review reported all adverse events to be mild or moderate in severity
and possibly attributable to malaria. [11]  It found no adverse cardiovascular effects. It found four
serious adverse events, but the authors did not consider these to be related to treatment.The RCT
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found no changes in QRS duration and PR interval during treatment in 66 people who had regular
electrocardiographic monitoring. Similarly, it found no differences in mean and median QTc (heart
rate-corrected QT interval) values between treatments.
Comment: Concealment was adequate.The trial was conducted in an area of multi-drug resistance.Transmis-
sion was not stated.
Clinical guide:
Evidence suggests that a six-dose regimen of artemether–lumefantrine is more effective than a
four-dose regimen.
OPTION ARTEMETHER–LUMEFANTRINE (6 DOSES) VERSUS ARTESUNATE (3 DAYS) PLUS
AMODIAQUINE (EXCLUDING SOUTH EAST ASIA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cure rates
Artemether–lumefantrine compared with artesunate plus amodiaquine We don’t know whether artemether–lumefantrine
may be more effective at increasing cure rates at 28 days compared with artesunate plus amodiaquine ( very low-
quality evidence ).
Recrudescence
Artemether–lumefantrine compared with artesunate plus amodiaquine Artemether–lumefantrine may be more effective
at reducing recrudescence rates at 28 days compared with artesunate plus amodiaquine ( low-quality evidence ).
For GRADE evaluation of interventions for malaria: uncomplicated, caused by Plasmodium falciparum, see
table, p 13 .
Benefits: We found one systematic review [3] and four subsequent RCTs [12] [13] [14] [15] that compared
artemether–lumefantrine (6-dose regimen) versus artesunate plus amodiaquine.The review (search
date 2005) identified one four-arm RCT. [4] It found that treatment with artemether–lumefantrine
resulted in a significant reduction in parasitological failures , but no difference in clinical failures
compared with amodiaquine plus artesunate after 28 days (1034 children randomised to artesunate
plus amodiaquine and artemether–lumefantrine arms, in Tanzania; polymerase chain reaction
[PCR]-unadjusted parasitological failure: 103/485 [21%] with artemether–lumefantrine v 193/472
[40%] with artesunate plus amodiaquine; OR 0.4, 95% CI 0.3 to 0.5; PCR-unadjusted clinical failure:
38/485 [8%] with artemether–lumefantrine v 52/472 [11%] with artesunate plus amodiaquine; OR
0.7, 95% CI 0.4 to 1.1). It found that artemether–lumefantrine significantly reduced gametocyte
carriage on day 14 compared with artesunate plus amodiaquine (gametocyte carriage on day 14:
20/333 [6%] with artemether–lumefantrine v 38/318 [12%] with artesunate plus amodiaquine; RR
0.50, 95% CI 0.30 to 0.84).The first subsequent RCT, a four-arm trial, found no difference between
the treatment groups in cure at day 28 (105 children aged 6-59 months randomised to artesunate
plus amodiaquine and artemether–lumefantrine arms in Ghana; adequate clinical and parasitolog-
ical response PCR-unadjusted day 28: 38/54 [70%] with artesunate plus amodiaquine v 39/51
[76%] with artemether–lumefantrine, significance assessment between groups not performed). [12]
It found that treatment with artesunate plus amodiaquine was associated with shorter fever clearance
times (fever clearance: 1.0 day with artesunate plus amodiaquine v 1.2 days with
artemether–lumefantrine; P = 0.006). Gametocytaemia peaked on day 1 (7/53 [13.2%] with arte-
sunate plus amodiaquine v 6/51 [11.8%] with artemether–lumefantrine) and declined to 2% on
days 7 and 14 (1/51 [2%] with artesunate plus amodiaquine v 1/47 [2%] with artemether–lume-
fantrine). [12] The second subsequent RCT found that treatment with artemether–lumefantrine was
associated with higher cure rates at day 28 compared with artesunate plus amodiaquine (408
children, Zanzibar; PCR-unadjusted day 28 cure rate: 183/197 [93%] with artemether–lumefantrine
v 149/206 [72%] with artesunate plus amodiaquine; OR 5.00, 95% CI 2.68 to 9.33, P less than
0.001; PCR-adjusted day 28 cure rate with uncertain results defined as reinfections: 192/197 [97%]
with artemether–lumefantrine v 193/206 [94%] with artesunate plus amodiaquine; OR 2.59, 95%
CI 0.9 to 7.40, P = 0.76; PCR-adjusted day 28 cure rate with uncertain results defined as recrude-
scences: 192/197 [97%] with artemether–lumefantrine v 188/206 [91%] with artesunate plus
amodiaquine; OR 3.68, 95% CI 1.34 to 10.10, P = 0.012). [13] It found that absence of fever on day
1 was observed in a significantly higher proportion of people treated with artesunate plus amodi-
aquine compared with artemether–lumefantrine (absence of fever on day 1: 162/205 [79%] with
artesunate plus amodiaquine v 134/199 [67%] with artemether–lumefantrine; OR 0.55, 95% CI
0.35 to 0.86, P = 0.008). It found that gametocyte carriage was similar in both groups (day 7, de-
tectable gametocyte counts: 4 children with artesunate plus amodiaquine v 1 child with
artemether–lumefantrine; further details not reported). [13] The third subsequent RCT (137 children
aged 6–59 months in Angola) found no difference in recurrent parasitaemia at day 28 or cure rate
at day 28 (PCR-unadjusted recurrent parasitaemia: 2/61 [3.2%] with artemether-lumefantrine v
4/64 [6.2%] with artesunate plus amodiaquine; P = 0.72; polymerase chain reaction-adjusted cure
rate: 100% with artemether–lumefantrine v 100% with artesunate plus amodiaquine, 95% CI,
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94–100% in both groups). [14]  Only one (1.5%) child in the artesunate plus amodiaquine group had
gametocytes on day 28 compared with five (7.3%) children in the artemether-lumefantrine group
and three (4.3%) children in the artesunate plus amodiaquine group at baseline. [14] The fourth
RCT (419 children aged 1–10 yrs in Uganda) found that the risk of recurrent symptomatic malaria
by day 28 was significantly lower for participants treated with artemether–lumefantrine than for
those treated with artesunate plus amodiaquine (unadjusted early treatment failure and late clinical
failure: 27% with artemether–lumefantrine v 42% with artesunate plus amodiaquine; risk difference
15%, 95% CI 5.9% to 24.2%, P = 0.001). [15]  It found a significant benefit in favour of
artemether–lumefantrine compared with artesunate plus amodiaquine for the risk of recurrent
parasitemia (unadjusted early treatment failure, late clinical failure, and late parasitological failure:
51% with artemether–lumefantrine v 66% with artesunate plus amodiaquine; risk difference 16%,
95% CI 6.2 to 25.2%, P = 0.001). This difference between groups was mostly caused by more late
clinical failures in the artesunate plus amodiaquine group (late clinical failure: 26% with
artemether–lumefantrine v 42% with artesunate plus amodiaquine; risk difference 16%, 95% CI
6.4% to 24.7%, P = 0.001 ); the risk of early treatment failure and late parasitological failure was
similar between the treatment groups (P = 1.0 and P = 0.89, respectively). Genotyping revealed
that nearly all episodes of recurrent malaria were because of new infections (PCR-adjusted recurrent
symptomatic malaria: 0/201 [0%] with artesunate plus amodiaquine v 2/202 [1%] with
artemether–lumefantrine; risk difference –1.0%; 95%CI –2.4% to 0.4%; PCR-adjusted recurrent
parasitaemia: 2/202 [0%] with artemether–lumefantrine v 0/201 [0%] with artesunate plus amodi-
aquine; risk difference –1%, 95% CI –2.4% to 0.4%).The proportion of participants with any game-
tocytes during follow-up was significantly lower in the artemether–lumefantrine group (20% with
artemether–lumefantrine v 31% with artesunate plus amodiaquine, reported as significant, P value
not provided). Similar results were found for participants with newly emerging gametocytes during
follow-up (5% with artemether–lumefantrine v 15% with artesunate plus amodiaquine, no statistical
test reported). [15]
Harms: The review did not report any harms for the included RCT. [3] The first subsequent RCT did not
report on adverse events. [12] The second subqequent RCT reported that both regimens were
generally well tolerated. [13] No deaths occurred, but 9 participants (7 with artesunate plus amodi-
aquine group v 2 with artemether–lumefantrine) developed clinically suspected severe malaria
during the follow-up period, and received rescue treatment (reported as no significant difference
between groups, P = 0.124). A severe or moderate adverse event was reported by 25/207 (12%)
children with artesunate plus amodiaquine compared with 21/200 (10%) children treated with
artemether–lumefantrine (unadjusted OR, 0.85; 95% CI, 0.46–1.58). All nine severe adverse events
were associated with clinically suspected severe malaria, and thus could not be attributed to the
intervention drugs by the authors of the trial. The third subsequent RCT did not report on harms.
[14] The fourth RCT assessed participants for any new or worsening adverse event at each follow-
up visit, and found that both treatments were well-tolerated. [15]  Overall, 261 (65%) of participants
experienced any adverse event of moderate or greater severity, and there was no significant differ-
ence between the two treatment groups (adverse event of at least moderate severity: 125/202
[62%] with artemether–lumefantrine v 136/201 [68%] with artesunate plus amodiaquine, P = 0.25).
No abnormalities in hearing or fine-finger dexterity were detected. Serious adverse events occurred
in two participants. One child treated with amodiaquine plus artesunate developed pneumonia on
day 27, requiring hospitalisation, but the event was judged unrelated to study medications. A second
participant, treated with artemether–lumefantrine, experienced a convulsion on day 0 which was
judged unlikely to be related to the study medication. [15]
Comment: The RCT [4] identified by the systematic review [3] used adequate allocation concealment. Malaria
transmission was perennial and the study site was in an area of chloroquine and sulfadox-
ine–pyrimethamine resistance. [4] In the first subsequent RCT allocation concealment was unclear.
[12]
 Malaria transmission was markedly seasonal, and the therapeutic efficacy of amodiaquine in
the study site was not reported. In the second subsequent RCT, allocation concealment was unclear,
and holoendemic transmission and resistance patterns were not stated. [13]  Inclusion criteria were
slightly different for very small children (less than 9 months or less than 9 kg body weight) because
both regimens were not similarly licensed; however, the numbers of children in each group were
similar. In the third additional RCT, allocation concealment was unclear; transmission was
mesoendemic, stable and seasonal. [14]  Drug resistance patterns were not stated. In the fourth
additional RCT, allocation concealment was unclear, malaria was holoendemic, and local drug re-
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sistance patterns were not stated. [15] Clinical guide: Both treatments were effective, but
artemether–lumefantrine (6 doses) was superior in some of the trials.
OPTION ARTEMETHER–LUMEFANTRINE (6 DOSES) VERSUS ARTESUNATE PLUS SULFADOX-
INE–PYRIMETHAMINE (EXCLUDING SOUTH EAST ASIA). . . . . . . . . . . . . . . . . . . . . . . . . . . .
We found no clinically important results about artemether–lumefantrine (6 doses) compared with artesunate
plus sulfadoxine–pyrimethamine in the treatment of people with uncomplicated malaria caused by plasmod-
ium falciparum.
For GRADE evaluation of Malaria: uncomplicated, caused by Plasmodium falciparum, see table, p 13 .
Benefits: We found no systematic reviews or RCTs that compared artemether–lumefantrine (6 doses) versus
artesunate plus sulfadoxine–pyrimethamine.
Harms: We found no RCTs.
Comment: Clinical guide:
Indirect comparisons suggest that artemether–lumefantrine may be more efficacious than artesunate
plus sulfadoxine–pyrimethamine.
OPTION ARTEMETHER–LUMEFANTRINE (6 DOSES) VERSUS ARTESUNATE (3 DAYS) PLUS
MEFLOQUINE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Treatment failure
Artemether–lumefantrine compared with artesunate plus mefloquine Artemether–lumefantrine seems to be no more
effective at reducing treatment failure rates at 28 days compared with artesunate plus mefloquine ( moderate-quality
evidence ).
Cure rates
Artemether–lumefantrine compared with artesunate plus mefloquine Artemether–lumefantrine may be no more ef-
fective at increasing cure rates at 42 days compared with artesunate plus mefloquine ( very low-quality evidence ).
For GRADE evaluation of interventions for malaria: uncomplicated, caused by Plasmodium falciparum, see
table, p 13 .
Benefits: We found one systematic review [3]  and two subsequent RCTs [16] [17] that compared
artemether–lumefantrine versus artesunate plus mefloquine. The systematic review found that
artemether–lumefantrine significantly increased treatment failures  compared with artesunate plus
mefloquine at 42 days (search date 2005, 2 RCTs, 315 people, in Lao People's Democratic Republic;
polymerase chain reaction [PCR]-unadjusted treatment failure: 27/154 [18%] with
artemether–lumefantrine v 10/161 [6%] with artesunate plus mefloquine; RR 2.93, 95% CI 1.48 to
5.80). [3] Two other RCTs identified by the review found no significant difference between
artemether–lumefantrine and artesunate plus mefloquine in total failure  rate after 28 days (2
RCTs, 389 people, in Thailand; PCR-unadjusted total failure rate; 11/289 [4%] with
artemether–lumefantrine v 0/100 [0%] with artesunate plus mefloquine; RR 4.20, 95% CI 0.55 to
31.93; PCR-adjusted total failure rate: 9/289 [3%] with artemether–lumefantrine v 0/100 [0%] with
artesunate plus mefloquine; RR 3.50, 95% CI 0.45 to 27.03). [3] The first subsequent RCT found
no significant difference between artemether–lumefantrine and artesunate plus mefloquine in cure
rates by day 42 (490 children and adults, in Thai–Myanmar border; PCR-adjusted cure rate: 98.8%
with artemether–lumefantrine v 96.3% with artesunate plus mefloquine; P = 0.08). [16] Parasite
clearance times were short, and most people were clear of parasitaemia by day 2. The second
subsequent three-arm RCT found no significant difference between artemether–lumefantrine and
artesunate plus mefloquine in PCR-adjusted adequate clinical and parasitological response (ACPR)
at 42 days (242 children and adults randomised to the artemether–lumefantrine and artesunate
plus mefloquine groups, in Bangladesh; PCR-adjusted ACPR rate: 99/102 [97%] with
artemether–lumefantrine v 105/105 [100%] with artesunate plus mefloquine; P = 0.12). [17]  However,
if new infections were included, then artesunate plus mefloquine reduced parasitological treatment
failure  rate at day 42 compared with artemether–lumefantrine (PCR-unadjusted parasitological
treatment failure: 20/121 [17%] with artemether–lumefantrine v 9/121 [7%] with artesunate plus
mefloquine; P = 0.039). [17]
Harms: One RCT included in the systematic review reported adverse events in treatment groups. [3]  It
found one case (1/47 [2%]) of severe diarrhoea with artemether–lumefantrine, but none with arte-
sunate plus mefloquine (0/50 [0%]; significance assessment not performed). The RCT reported
gastrointestinal events and central nervous system disorders in both groups (gastrointestinal events:
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6/47 [13%] with artemether–lumefantrine v 6/50 [12%] with artesunate plus mefloquine; significance
assessment not performed). Central nervous system disorders were more common with artesunate
plus mefloquine (14/47 [30%] with artemether–lumefantrine v 22/53 [41.5%] with artesunate plus
mefloquine; significance assessment not performed). One RCT reported adverse cardiac events
separately, and found no clinically significant changes in the electrocardiographic intervals. Another
RCT reported cardiac monitoring, and found no difference in the QTc interval (difference between
the longest and shortest measurable interval on the 12-lead electrocardiogram, corrected for heart
rate) between treatment groups. The first subsequent RCT reported no serious adverse events in
either treatment group. [16]  It found no significant difference between groups in numbers who
vomited one or more doses of medication (AR for vomiting: 5/242 [2.1%] with artemether–lume-
fantrine v 2/242 [0.8%] with artesunate plus mefloquine; RR 2.5, 95% CI 0.5 to 12.7). Common
mild adverse effects included gastrointestinal problems (abdominal pain, anorexia, nausea, diarrhoea
and late vomiting [e.g. greater than 1 hour] after administration of treatment) and central nervous
system effects (headache, dizziness). Overall, fewer people experienced adverse events with
artemether–lumefantrine than with artesunate plus mefloquine, although this difference was not
statistically significant (results presented graphically, difference reported as not significant, figures
not reported).The second additional RCT reported no severe adverse clinical events. [17] The study
reported that the frequency of mild adverse events (headache, nausea, vomiting, dizziness) was
significantly higher with artesunate plus mefloquine than with artemether–lumefantrine (mild adverse
events: results presented graphically; P less than 0.05). Other adverse events included sleepless-
ness, anorexia, skin itching/rash, epigastric pain, and excessive sweating, with artesunate plus
mefloquine, and blurred vision and anorexia with artemether–lumefantrine.
Comment: Concealment was adequate in three of the RCTs included in the systematic review, and unclear
in one. [3] The RCTs conducted in Lao People's Democratic Republic were in areas of chloroquine
and sulfadoxine–pyrimethamine resistance. Transmission was not specified in one trial, and was
perennial in the other. The two trials conducted in Thailand included in the systematic review were
in areas of low transmission. Resistance was not specified in one trial, and multi-drug resistance
was reported in another. In the subsequent RCTs, allocation concealment was unclear. [16] [17]
The first additional RCT was conducted in an area of multidrug resistance with low and unstable
transmission reported. [16] The second additional RCT reported sulfadoxine–pyrimethamine resis-
tance in an area of seasonal transmission. [17]
Clinical guide:
Artesunate plus mefloquine performs better than artemether–lumefantrine in terms of cure in areas
where this has been studied.
OPTION ARTESUNATE PLUS AMODIAQUINE VERSUS ARTESUNATE PLUS SULFADOX-
INE–PYRIMETHAMINE (EXCLUDING SOUTH EAST ASIA). . . . . . . . . . . . . . . . . . . . . . . . . . . .
Response rates
Artesunate plus amodiaquine compared with artesunate plus sulfadoxine–pyrimethamine We don’t know whether
artesunate plus amodiaquine is any more effective at increasing response rates at 28 days compared with artesunate
plus sulfadoxine–pyrimethamine ( very low-quality evidence ).
Treatment failure
Artesunate plus amodiaquine compared with artesunate plus sulfadoxine–pyrimethamine Artesunate plus amodiaquine
is more effective at reducing treatment failure rates at 28 days compared with artesunate plus sulfadox-
ine–pyrimethamine ( moderate-quality evidence ).
For GRADE evaluation of Malaria: uncomplicated, caused by Plasmodium falciparum, see table, p 13 .
Benefits: We found three RCTs that compared artesunate plus amodiaquine versus artesunate plus sulfa-
doxine–pyrimethamine. [18] [19] [20] The first RCT found no significant difference in adequate clinical
and parasitological response rate (ACPR) after 28 days between artesunate plus amodiaquine and
artesunate plus sulfadoxine–pyrimethamine (161 children aged 6–59 months, in Sudan; polymerase
chain reaction [PCR]-adjusted ACPR: 51/55 [93%] with artesunate plus amodiaquine v 52/57 [91%]
with artesunate plus sulfadoxine–pyrimethamine; difference reported as not significant, figures not
reported). [18]  It found similar treatment failure rates in both groups at day 28 (PCR-unadjusted
clinical or parasitological treatment failure: 29/80 [36%] with artesunate plus amodiaquine v 27/79
[34%] with artesunate plus sulfadoxine–pyrimethamine; PCR-adjusted treatment failure: 4/55 [7%]
with artesunate plus amodiaquine v 5/57 [9%] with artesunate plus sulfadoxine–pyrimethamine;
significance assessments not performed). [18] The study reported that most children were afebrile
by day 2, and gametocyte carriage remained low throughout the study (afebrile at day 2: 79/80
[99%] with artesunate plus amodiaquine v 78/81 [96%] with artesunate plus sulfadox-
ine–pyrimethamine; significance assessment not performed; day 14 gametocyte carriage: 3/80
[4%] with artesunate plus amodiaquine v 4/79 [5%] with artesunate plus sulfadoxine–pyrimethamine;
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day 28 gametocyte carriage: 2/68 [3%] with artesunate plus amodiaquine v 2/70 [3%] with artesunate
plus sulfadoxine–pyrimethamine; significance assessments not performed). The second quasi-
randomised RCT found a significantly higher rate of adequate clinical and parasitological response
at day 28 with artesunate plus sulfadoxine–pyrimethamine compared with artesunate plus amodi-
aquine (269 children aged 6–59 months, in Sudan; PCR-unadjusted ACPR rate: 105/117 [90%]
with artesunate plus amodiaquine v 114/116 [98%] with artesunate plus sulfadoxine–pyrimethamine;
P = 0.014). [19]  In this RCT, treatment groups were allocated by alternate allocation. The third RCT
found that treatment with artesunate plus amodiaquine was associated with a lower rate of treatment
failure by day 28 compared with artesunate plus sulfadoxine–pyrimethamine, regardless of whether
new infections were included or not (180 children aged 6–59 months, in the Democratic Republic
of Congo; failure rate PCR unadjusted: 14/83 [17%] with artesunate plus amodiaquine v 28/81
[35%] with artesunate plus sulfadoxine–pyrimethamine; P = 0.009; PCR-adjusted failure rate: 5/74
[7%] with artesunate plus amodiaquine v 13/66 [20%] with artesunate plus sulfadox-
ine–pyrimethamine; P = 0.02). [20]  It found that fever clearance was complete within 2–3 days for
both therapies, and found no significant difference between the two groups (no further data or P
value reported) . It reported that the two treatment groups did not show a significant difference in
gametocyte clearance rates (no P value reported). [20]
Harms: The first RCT reported that there were "no significant adverse events" in either group. [18] The
second RCT found no adverse events in either group during follow-up. [19] In the third RCT, parents
or guardians were asked for any potential side effects of the drugs, and the child’s tolerability to
the treatment at follow-up. [20]  It stated that no adverse effects were reported, and that both drug
regimens were well tolerated.
Comment: In the first RCT, allocation concealment was adequate. [18] The study site exhibited marked sea-
sonal transmission of malaria. No data for antimalarial efficacy were available. Allocation conceal-
ment was inadequate in the second quasi-randomised RCT, and losses to follow-up were high
(15%). [19] This study was conducted in an area of medium to high malaria endemicity. In the third
RCT, allocation concealment was adequate. [20]  Malaria in the Democratic Republic of Congo is
highly endemic and seasonal, with intense perennial transmission. Details of the drug regimens
used were not stated in this study.
Clinical guide:
The choice between artesunate plus amodiaquine and artesunate plus sulfadoxine–pyrimethamine
depends on background drug resistance patterns in the relevant country or region.
GLOSSARY
Adequate clinical and parasitological response (ACPR) According to the World Health Organization definition,
absence of parasitaemia at day 28 irrespective of axillary temperature and without previously meeting any of the
World Health Organization criteria for early or late treatment failure, or late parasitological failure. [21]
Clinical failure Symptoms of malaria with parasitaemia on or before day 28.
Gametocytaemia Microscopic evidence of gametocytes in the blood.
Gametocyte clearance time Time to clearance of gametocytes from the blood after treatment.
Parasitological conversion Clearance of parasitaemia within a specified time after treatment.
Parasitological failure Parasitaemia detected within a specified time after treatment.
Parasitological success Absence of parasitaemia within a specified time after treatment.
Polymerase chain reaction (PCR) adjusted treatment failure rate Parasitaemia on or by day 28 may be due to
recrudescence of the original infection or caused by a new infection. PCR adjusted values exclude parasitaemia
caused by a new infection.
Total failure People presenting with clinical failure or with parasitaemia on day 28.
Treatment failure This term is used loosely in the literature but it generally means total failure or failure (clinical or
parasitological) within the period of follow up.The World Health Organization modified definitions of treatment failure
in 2003 to include late parasitological failures. [21]
High-quality evidence Further research is very unlikely to change our confidence in the estimate of effect
Low-quality evidence Further research is very likely to have an important impact on our confidence in the estimate
of effect and is likely to change the estimate.
Moderate-quality evidence Further research is likely to have an important impact on our confidence in the estimate
of effect and may change the estimate.
Very low-quality evidence Any estimate of effect is very uncertain.
SUBSTANTIVE CHANGES
Artemether–lumefantrine (6 doses) versus artemether–lumefantrine (4 doses) One systematic review added;
[10] benefits and harms data enhanced, categorisation unchanged (Likely to be beneficial).
Artemether–lumefantrine (6 doses) versus artesunate (3 days) plus amodiaquine (excluding South East Asia)
Four RCTs added; [12] [13] [14] [15] benefits and harms data enhanced, categorisation unchanged (Likely to be
beneficial).
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Artesunate plus amodiaquine versus artesunate plus sulfadoxine–pyrimethamine (excluding South East
Asia) One RCT added; [20] benefits and harms data enhanced, categorisation unchanged (Unknown effectiveness).
Artesunate (3 days) plus amodiaquine versus amodiaquine plus sulfadoxine–pyrimethamine One RCT added;
[6]
 benefits and harms data enhanced, categorisation changed from Likely to be beneficial to Trade-off between
benefits and harms.
Artesunate (3 days) plus sulfadoxine–pyrimethamine versus amodiaquine plus sulfadoxine–pyrimethamine
One systematic review [7] and two RCTs added; [8] [9] benefits and harms data enhanced, categorisation changed
from Unknown effectiveness to Unlikely to be beneficial.
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TABLE GRADE evaluation of interventions for malaria: uncomplicated, caused by Plasmodium fal-
ciparum






















Are artemisinin combination treatments more effective than non-artemisinin combination treatments in people living in endemic areas
(excluding South East Asia)?
Effect size point added for









Quality point deducted for in-
complete reporting of results








Quality point deducted for in-










Quality point deducted for in-










Quality point deducted for














Which artemisinin combination treatment is most effective in people living in endemic areas?
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Type of evidence: 4 = RCT; 2 = Observational; 1 = Non-analytical/expert opinion.
Consistency: similarity of results across studies.
Directness: generalisability of population or outcomes.
Effect size: based on relative risk or odds ratio.
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